Sorry!! The article you are trying to read is not available now.
By: Benzinga
Curis Announces Worldwide Licensing Rights for IAP Inhibitor GDC-0917 From Genentech
Curis (NASDAQ: CRIS ), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that it has licensed from Genentech, a member of the Roche Group, (OTC: RHHBY ), exclusive, worldwide rights for the development and commercialization of GDC-0917,
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here